Similar to hyperglycemia, higher fasting serum insulin or C-peptide (a marker of insulin production) levels are also associated with poor prognosis in breast cancer patients.  A 1 ng/mL increase in serum C-peptide level (>2.5 ng/mL vs <1.7 ng/mL; normal levels=0.5-2.0 ng/mL) was associated with 35% increase in death due to breast cancer, and 31% increase in overall risk of death. This risk was skewed towards patients with type 2 diabetes, estrogen receptor positive cancers and higher stage disease.11  These observations suggest that lowering glycemia and C-peptide levels may significantly improve prognosis, and managing diabetes in breast cancer patients must be part of oncology care.

Metformin, a widely used antidiabetic medication, was shown to improve the breast cancer treatment response rate in type 2 diabetic patients.  A study of 2529 early breast cancer patients receiving neoadjuvant chemotherapy showed that diabetic patients on a metformin regimen achieved a 24% pathological complete response (pCR) while the rate of pCR was 8% in the nonmetformin group and 16% in nondiabetic cancer patients.12  Interestingly, other classes of antidiabetic drugs do not appear to confer survival advantage, and in fact, may increase the risk of cancer and worsen cancer prognosis.13  Metformin’s antiproliferative effect on breast cancer cells in vitro can be explained by the following mechanisms: it directly inhibits mTOR cell proliferative pathway; indirectly acts by decreasing insulin levels and activating adenosine monophosphate-activated protein kinase cell signaling; and also targets breast cancer stem cells.14,15


Continue Reading

In summary, multiple studies suggest a correlative relationship between diabetes and poor prognosis or increased risk of breast cancer; however, a cause-and-effect relationship is not clear.  Nevertheless, available data and clinical experiences provide strong rationale for bringing internists and oncologists into the same room and including diabetes management as part of the breast cancer treatment program.


REFERENCES

1. Wilson EB, Maher HC. Cancer and tuberculosis, with some comments on cancer and other diseases. Am J Cancer. 1932;16:227-250.

2. Marble A. Diabetes and cancer. N Engl J Med. 1934;211(8):339-349.

3. Chowdhury TA. Diabetes and cancer. QJM. 2010;103(12):905-915.

4. Wolf I, Sadetzki S, Catane R, et al. Diabetes mellitus and breast cancer. Lancet Oncol. 2005;6(2):103-111.

5. Erickson K, Patterson RE, Flatt SW, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol. 2011;29(1):54-60.

6. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011;29(1):40-46.

7. DeCensi A, Gennari A. Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol. 2011;29(1):7-10.

8. Ferguson RD, Novosyadlyy R, Fierz Y, et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res. 2012;14(1):R8.

9. Ono M. Scripps Florida scientists uncover inflammatory circuit that triggers breast cancer. Findings point to potentially effective new therapeutic target for cancer treatment and prevention [online]. EurekAlert.org. February 23, 2012. http://www.eurekalert.org/pub_releases/2012-02/sri-sfs022312.php. Accessed February 28, 2012.

10. Sun G, Kashyap SR. Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. J Nutr Metab. 2011;2011:708183.

11. Irwin ML, Duggan C, Wang CY, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol. 2011;29(1):47-53.

12. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297-3302.

13. Beck S. Diabetes, diabetes drugs, and cancer risk: the potentials for prevention [online]. Cancer Network. June 8, 2011. http://www.cancernetwork.com/conference-reports/asco2011/content/article/10165/1874808. Accessed: February 13, 2012.

14. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010;16(6):1695-1700.

15. Jung JW, Park SB, Lee SJ, et al. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One. 2011;6(11):e28068.